Plain-English translation of NCT06323239 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new approach for people whose nasopharyngeal cancer (a type of cancer in the upper throat) has come back or spread to other parts of the body. The treatment combines two types of radiation therapy with a medication called a PD-1 antibody plus chemotherapy. Researchers want to see if combining these treatments together works better than previous approaches and to understand what side effects people might experience.
People with nasopharyngeal cancer that returns or spreads have limited treatment options and often don't survive as long as doctors would hope. This medication works by helping your body's immune system recognize and fight cancer cells, and the researchers believe combining it with radiation and chemotherapy might be more effective than any single treatment alone.
You likely qualify if…
You likely don't qualify if…
You would receive radiation therapy one day before starting cycles of chemotherapy combined with the immune-boosting medication. This combination phase would last about six cycles, after which you would continue receiving the immune medication alone until either your cancer progresses, you experience side effects that are too severe, or you've received the medication for up to two years. You'll have regular clinic visits and scans to monitor how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China